Loading...
Docoh

Exelixis (EXEL)

Utility
Method of Preparing Fluorine-18 Labeled Cabozantinib and Its Analogs
23 Jun 22
The present invention relates to a method of preparing Cabozantinib (Cyclopropane-1,1-dicarboxylic acid [4-(6,7-di-methoxy-quinolin-4-vloxy)-phenyl]amide (4-fluoro-phenyl)amide) and 18F labeled Cabozantinib.
Wei Xu, David J. Donnelly, Patrick L. Chow, Benjamin J. Henley
Filed: 3 Sep 21
Utility
Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds
9 Jun 22
Jo Ann Wilson, Khalid Shah
Filed: 24 Feb 22
Utility
Crystalline Solid Forms of Salts of N-{4-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PHENYL}-N'-(4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE, Processes for Making, and Methods of Use
26 May 22
The invention relates to novel crystalline solid forms of salts of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and solvates thereof, including hydrates, that are useful for the treatment of cancer.
Khalid Shah
Filed: 9 Feb 22
Utility
C-Met Modulator Pharmaceutical Compositions
24 Mar 22
Jo Ann Wilson, Khalid Shah
Filed: 30 Nov 21
Utility
Compounds for the Treatment of Kinase-Dependent Disorders
24 Mar 22
The present invention relates to compounds that modulate cellular activities such as proliferation, differentiation, programmed cell death, migration, and chemoinvasion, by modulating protein kinase enzymatic activity, and compositions thereof, and methods of using such compounds.
Lynne Canne Bannen, Faming Jiang, Kin Tso, Xu Wei
Filed: 24 Jan 20
Utility
Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
22 Mar 22
The invention relates to novel crystalline solid forms of salts of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and solvates thereof, including hydrates, that are useful for the treatment of cancer.
Khalid Shah
Filed: 26 May 18
Utility
Crystalline Fumarate Salt of (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)PHENYL] [3-HYDROXY-3-(PIPERIDIN-2-YL) AZETIDIN-1-YL]-METHANONE
24 Feb 22
This disclosure relates to the crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methamine.
Adrian St. Clair Brown
Filed: 8 Nov 21
Utility
Combinations of Cabozantinib and Atezolizumab to Treat Cancer
24 Feb 22
This invention relates to the combination of cabozantinib and atezolizumab to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma.
Gisela Schwab, Christian Scheffold, Colin Hessel
Filed: 4 Nov 21
Utility
Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone
22 Feb 22
This disclosure relates to the crystalline fumarate salt of (S)[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone.
Adrian St. Clair Brown
Filed: 17 Jan 20
Utility
C-Met Modulator Pharmaceutical Compositions
3 Feb 22
Jo Ann Wilson, Khalid Shah
Filed: 19 Oct 21
Utility
Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
3 Feb 22
Disclosed are malate salts of N-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclo-propane-1,1-dicarboxamide, including a (L)-malate salt, a (D)-malate salt, a (DL) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts.
Adrian St. Clair Brown, Peter Lamb, William P. Gallagher
Filed: 19 Oct 21
Utility
Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds
27 Jan 22
Jo Ann Wilson, Khalid Shah
Filed: 8 Oct 21
Utility
Method of Treating Renal Cell Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
6 Jan 22
The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
Dana T. Aftab, Gisela Schwab, Colin Hessel, Christian Scheffold, Steven Lacy, Dale Miles, Alan Arroyo, Mark Dean
Filed: 7 Sep 21
Utility
Combinations of cabozantinib and atezolizumab to treat cancer
14 Dec 21
This invention relates to the combination of cabozantinib and atezolizumab to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma.
Gisela Schwab, Christian Scheffold, Colin Hessel
Filed: 19 Jan 18
Utility
C-Met Modulator Pharmaceutical Compositions
9 Dec 21
Jo Ann Wilson, Khalid Shah
Filed: 23 Aug 21
Utility
Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
28 Oct 21
Disclosed are malate salts of N-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, including a (L)-malate salt, a (D)-malate salt, a (DL) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts.
Adrian St. Clair Brown, Peter Lamb, William P. Gallagher
Filed: 9 Jul 21
Utility
Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
12 Oct 21
The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti-angiogenic therapy using CABOMETYX, a kinase inhibitor.
Dana T. Aftab, Gisela Schwab, Colin Hessel, Christian Scheffold, Steven Lacy, Dale Miles, Alan Arroyo, Mark Dean
Filed: 17 Apr 17
Utility
Heterocyclic Adenosine Receptor Antagonists
23 Sep 21
Heterocyclic compounds useful as antagonists of adenosine receptors, and methods of treatment of diseases using antagonists of adenosine receptors are disclosed herein.
Sunghoon Ma, Yong Wang, Wei Xu
Filed: 15 Mar 21
Utility
C-met modulator pharmaceutical compositions
21 Sep 21
Jo Ann Wilson, Khalid Shah
Filed: 20 Dec 19
Utility
Method of preparing fluorine-18 labeled Cabozantinib and its analogs
21 Sep 21
The present invention relates to a method of preparing Cabozantinib (Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenylo]amide(4-fluoro-phenyl)amide) and 18F labeled Cabozantinib.
Wei Xu, David J. Donnelly, Patrick L. Chow, Benjamin J. Henley
Filed: 31 Jul 15
Patents are sorted by USPTO publication date, most recent first